Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02636049 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetics of Triferic (Ferric Pyrophosphate Citrate) Administered Intravenously to Healthy Adult Volunteers
A Phase 1 study, sponsored by Rockwell Medical Technologies.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT02636049 is a Phase 1 study that has completed, run by Rockwell Medical Technologies. The registered enrollment target is 12 participants.
The verdict
NCT02636049, a Phase 1 study, has completed, sponsored by Rockwell Medical Technologies.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
This is a Phase 1, open-label, three-period sequential dosing study being conducted to determine the pharmacokinetics of Triferic iron administered intravenously (IV) to healthy adults.
Interventions
- DRUG Triferic
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2015-10 |
| Est. Completion | 2015-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02636049
The ClinicalTrials.gov registry entry for NCT02636049 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rockwell Medical Technologies, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Triferic is the first listed.
NCT02636049 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02636049 about?
NCT02636049 is a clinical study titled "Pharmacokinetics of Triferic (Ferric Pyrophosphate Citrate) Administered Intravenously to Healthy Adult Volunteers". This is a Phase 1, open-label, three-period sequential dosing study being conducted to determine the pharmacokinetics of Triferic iron administered intravenously (IV) to healthy adults.
What is the current status of trial NCT02636049?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2015-10. Estimated completion is 2015-10.
What interventions are being tested in trial NCT02636049?
The interventions under investigation include: Triferic (DRUG).
Who is sponsoring clinical trial NCT02636049?
This trial is sponsored by Rockwell Medical Technologies, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.